Despite a further decline in consensus revenue growth forecasts, Astellas Pharma’s analyst price target inched up from ¥1708 to ¥1725, reflecting only a marginal increase in perceived fair value.
What's in the News
- Positive Phase 3 results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin; significant improvement in event-free and overall survival compared to surgery alone, with consistent safety profiles.
- Memorandum of understanding signed with Korea Institute of Startup and Entrepreneurship Development to support Korean drug-discovery startups, providing access to Astellas’ research facilities; two companies, TCUBEiT Inc. and AAVATAR Therapeutics, selected for collaboration.
- Positive overall survival results from Phase 3 EMBARK study for XTANDI (enzalutamide) plus leuprolide in non-metastatic hormone-sensitive prostate cancer; combination met secondary OS endpoint, no new safety signals.
- Preliminary U.S. sales of IZERVAY (avacincaptad pegol) for geographic atrophy totaled $110 million in Q1 FY2025.
- XTANDI (enzalutamide) now reimbursed under Ontario Drug Benefit Program for high-risk non-metastatic castration-sensitive prostate cancer, expanding public access in Canada.
Valuation Changes
Summary of Valuation Changes for Astellas Pharma
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from ¥1708 to ¥1725.
- The Consensus Revenue Growth forecasts for Astellas Pharma has significantly fallen from -1.3% per annum to -1.6% per annum.
- The Future P/E for Astellas Pharma remained effectively unchanged, moving only marginally from 19.08x to 19.27x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.